Page 11234..1020..»

Category Archives: Global News Feed

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Posted: January 13, 2025 at 2:54 am

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA

Visit link:
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Posted in Global News Feed | Comments Off on Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

Posted: January 13, 2025 at 2:54 am

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance.

Excerpt from:
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

Posted in Global News Feed | Comments Off on Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

Virbac : Declaration of the number of shares and voti

Posted: January 13, 2025 at 2:54 am

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Read this article:
Virbac : Declaration of the number of shares and voti

Posted in Global News Feed | Comments Off on Virbac : Declaration of the number of shares and voti

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Posted: January 13, 2025 at 2:54 am

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.

More:
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Posted in Global News Feed | Comments Off on Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: January 13, 2025 at 2:54 am

WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

Read the original post:
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Matinas BioPharma Receives NYSE Noncompliance Notice

Posted: January 13, 2025 at 2:54 am

BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide.

More:
Matinas BioPharma Receives NYSE Noncompliance Notice

Posted in Global News Feed | Comments Off on Matinas BioPharma Receives NYSE Noncompliance Notice

Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Posted: January 13, 2025 at 2:54 am

-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix

Read the original here:
Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Posted in Global News Feed | Comments Off on Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160…

Posted: January 13, 2025 at 2:54 am

WESTLAKE VILLAGE, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced certain preliminary unaudited financial information for the fourth quarter and full-year 2024.

See the article here:
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160...

Posted in Global News Feed | Comments Off on Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160…

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Posted: January 13, 2025 at 2:54 am

2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1

See original here:
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Posted in Global News Feed | Comments Off on Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Posted: January 13, 2025 at 2:54 am

- Ascendis positioned to drive rapid revenue growth

Go here to see the original:
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Posted in Global News Feed | Comments Off on Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Page 11234..1020..»